Holen Sie sich die Stockscreener-App
5.31
0.57%
0.03
Schlusskurs vom Vortag:
$5.28
Offen:
$5.34
24-Stunden-Volumen:
2.38M
Relative Volume:
1.46
Marktkapitalisierung:
$489.52M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+0.00%
1M Leistung:
-1.48%
6M Leistung:
+33.42%
1J Leistung:
+244.81%
1-Tages-Spanne:
$4.995
$5.34
1-Wochen-Bereich:
$4.78
$5.47
52-Wochen-Spanne:
$1.48
$5.98
Atyr Pharma Inc Stock (ATYR) Company Profile
Firmenname
Atyr Pharma Inc
Sektor
Branche
Telefon
(858) 731-8389
Adresse
10240 SORRENTO VALLEY ROAD, SAN DIEGO
Vergleichen Sie ATYR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ATYR
Atyr Pharma Inc
|
5.31 | 489.52M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.62 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.36 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
331.91 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
543.48 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.49 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Atyr Pharma Inc Stock (ATYR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-18 | Eingeleitet | Leerink Partners | Outperform |
| 2025-01-06 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-10-04 | Eingeleitet | Wells Fargo | Overweight |
| 2024-09-05 | Eingeleitet | Jefferies | Buy |
| 2023-07-05 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2021-10-12 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-09-21 | Eingeleitet | Piper Sandler | Overweight |
| 2021-05-10 | Eingeleitet | Laidlaw | Buy |
| 2020-08-17 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2020-03-04 | Eingeleitet | ROTH Capital | Buy |
| 2020-03-02 | Eingeleitet | Oppenheimer | Outperform |
| 2018-02-14 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2017-09-07 | Eingeleitet | Piper Jaffray | Overweight |
| 2016-12-13 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2015-12-16 | Eingeleitet | Citigroup | Neutral |
| 2015-06-01 | Eingeleitet | Citigroup | Buy |
| 2015-06-01 | Eingeleitet | JP Morgan | Overweight |
Alle ansehen
Atyr Pharma Inc Aktie (ATYR) Neueste Nachrichten
With 70% ownership, aTyr Pharma, Inc. (NASDAQ:ATYR) boasts of strong institutional backing - Yahoo Finance
Bank of America Corp DE Makes New $330,000 Investment in Atyr PHARMA INC (NASDAQ:ATYR) - MarketBeat
Cantor Fitzgerald Comments on Atyr PHARMA FY2026 Earnings - MarketBeat
Two Sigma Investments LP Takes Position in Atyr PHARMA INC (NASDAQ:ATYR) - Defense World
91,224 Shares in Atyr PHARMA INC (NASDAQ:ATYR) Bought by Bank of America Corp DE - Defense World
Atyr PHARMA (NASDAQ:ATYR) Stock Price Up 6.1%Here's Why - MarketBeat
Cantor Fitzgerald Estimates Atyr PHARMA FY2026 Earnings - Defense World
aTyr: Promising Data But Cash May Be An Issue (NASDAQ:ATYR) - Seeking Alpha
Squarepoint Ops LLC Invests $96,000 in Atyr PHARMA INC (NASDAQ:ATYR) - Defense World
Two Sigma Advisers LP Makes New $44,000 Investment in Atyr PHARMA INC (NASDAQ:ATYR) - Defense World
Millennium Management LLC Makes New Investment in Atyr PHARMA INC (NASDAQ:ATYR) - MarketBeat
H.C. Wainwright reaffirms aTyr Pharma stock with a $35 price target - Investing.com UK
Atyr PHARMA (NASDAQ:ATYR) Receives Buy Rating from HC Wainwright - Defense World
aTyr Pharma reports positive interim results for SSc-ILD treatment By Investing.com - Investing.com South Africa
aTyr Pharma Announces Findings from Interim Analysis of - GlobeNewswire
ATYR Stock Update: HC Wainwright Reiterates 'Buy' Rating with $3 - GuruFocus
ATYR Stock Update: HC Wainwright Reiterates 'Buy' Rating with $35 Price Target | ATYR Stock News - GuruFocus
aTyr Pharma reports positive interim results for SSc-ILD treatment - Investing.com Australia
aTyr Pharma (ATYR) Reports Promising Interim Results for Efzofitimod | ATYR Stock News - GuruFocus
aTyr Pharma Announces Findings from Interim Analysis of Ongoing Phase 2 EFZO-CONNECT™ Study of Efzofitimod in Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD) - GlobeNewswire
Millennium Management LLC Takes $1.33 Million Position in Atyr PHARMA INC (NASDAQ:ATYR) - Defense World
Breakthrough: aTyr's New Drug Shows Promising Results in 75% of Severe Scleroderma Patients - Stock Titan
aTyr Pharma (ATYR) Scheduled for Key Presentation in New York | - GuruFocus
aTyr Pharma (ATYR) Scheduled for Key Presentation in New York | ATYR Stock News - GuruFocus
aTyr Pharma stock soars to 52-week high of $4.66 By Investing.com - Investing.com Nigeria
Atyr PHARMA INC (NASDAQ:ATYR) Receives Average Recommendation of "Buy" from Analysts - MarketBeat
182,625 Shares in Atyr PHARMA INC (NASDAQ:ATYR) Bought by Northern Trust Corp - Defense World
Woodline Partners LP Purchases New Position in Atyr PHARMA INC (NASDAQ:ATYR) - MarketBeat
Atyr PHARMA INC (NASDAQ:ATYR) Receives Consensus Recommendation of “Buy” from Brokerages - Defense World
High Growth Tech Stocks in the US to Watch This May 2025 - Yahoo Finance
Group One Trading LLC Takes $26,000 Position in Atyr PHARMA INC (NASDAQ:ATYR) - Defense World
Jane Street Group LLC Invests $720,000 in Atyr PHARMA INC (NASDAQ:ATYR) - Defense World
aTyr Pharma’s SWOT analysis: biotech firm’s stock poised for potential breakthrough - Investing.com India
aTyr Pharma’s SWOT analysis: biotech firm’s stock poised for potential breakthrough By Investing.com - Investing.com South Africa
aTyr Pharma, Inc. (ATYR): Analysts See 485% Upside Potential - Insider Monkey
aTyr Pharma to Present at Upcoming Investor Conferences - GlobeNewswire
aTyr Pharma Announces Triple Conference Schedule: RBC, Jefferies, and Piper Sandler Healthcare Events Coming Up - Stock Titan
aTyr Pharma (ATYR) Highlights Efzofitimod Research at ATS 2025 | ATYR Stock News - GuruFocus
aTyr Pharma (ATYR) Highlights Efzofitimod Research at ATS 2025 | - GuruFocus
aTyr Pharma (ATYR) Receives Steady 'Buy' Rating from HC Wainwright | ATYR Stock News - GuruFocus
Such Is The Power Of Atyr Pharma Inc (NASDAQ: ATYR) - Stocksregister
aTyr Pharma Presents Three Posters on Efzofitimod at the - GlobeNewswire
Breakthrough Phase 3 Trial Reveals 158,900 Patients Could Benefit from New Sarcoidosis Treatment - Stock Titan
Balyasny Asset Management L.P. Buys Shares of 44,310 Atyr PHARMA INC (NASDAQ:ATYR) - Defense World
aTyr Pharma Presents Three Posters on Efzofitimod at the American Thoracic Society (ATS) 2025 International Conference - The Manila Times
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rul - GuruFocus
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
ATyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - marketscreener.com
Dimensional Fund Advisors LP Makes New $881,000 Investment in Atyr PHARMA INC (NASDAQ:ATYR) - Defense World
Finanzdaten der Atyr Pharma Inc-Aktie (ATYR)
Es liegen keine Finanzdaten für Atyr Pharma Inc (ATYR) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
Atyr Pharma Inc-Aktie (ATYR) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Broadfoot Jill Marie | Chief Financial Officer |
Feb 04 '25 |
Sale |
3.78 |
1,254 |
4,740 |
31,763 |
| DENYES NANCY | General Counsel |
Feb 04 '25 |
Sale |
3.78 |
899 |
3,398 |
26,555 |
| SCHIMMEL PAUL | Director |
Jul 24 '24 |
Buy |
1.93 |
52,300 |
101,038 |
413,023 |
| SCHIMMEL PAUL | Director |
Jul 22 '24 |
Buy |
1.74 |
41,052 |
71,500 |
354,075 |
| SCHIMMEL PAUL | Director |
Jul 23 '24 |
Buy |
1.82 |
6,648 |
12,075 |
360,723 |
0.68%
0.50%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):